What is Johnson & Johnson's full-year 2026 revenue guidance?

The company raised its full-year sales guidance to a range of $100.8 billion to $101.4 billion.

Which device recently received FDA approval?

The dual energy THERMOCOOL SMARTTOUCH SF catheter received FDA approval for cardiac arrhythmia treatment.

Johnson & Johnson (JNJ) Raises Dividend, Updates Revenue Guidance

Johnson & Johnson (JNJ) declared a Q3 2026 cash dividend of $1.34 per share, shortly after raising its full-year revenue guidance to $100.8B-$101.4B and securing FDA approval for its dual energy THERMOCOOL SMARTTOUCH SF catheter.

July 22, 2026

1 min read

Source: Simply Wall St.

Key Numbers

dividend per share

1.34

revenue guidance low

100.8B

revenue guidance high

101.4B

Johnson & Johnson (JNJ) has declared a third quarter 2026 cash dividend of $1.34 per share, providing income-focused investors with updated information on the stock's payout profile and upcoming key dates.

Dividend Details

The company announced a cash dividend of $1.34 per share for the third quarter of 2026. This follows the release of second quarter 2026 results.

Guidance Update

Johnson & Johnson raised its full-year 2026 sales guidance to a range of $100.8 billion to $101.4 billion, reflecting positive growth expectations.

FDA Approval

The company recently secured FDA approval for its dual energy THERMOCOOL SMARTTOUCH SF catheter, used in cardiac arrhythmia treatment.

What This Means for Investors

The dividend increase and guidance raise underscore the company's solid financial performance. However, investors should assess the stock's fair value through comprehensive fundamental analysis.

Frequently Asked Questions

The company declared a Q3 2026 cash dividend of $1.34 per share.

Found this useful? Share it

This article was rewritten in Wrqti's editorial style based on information from the original source above. Content is informational only — not investment advice.